REG - Arecor Therapeutics - Result of AGM

Arecor TherapeuticsAnnouncement

28/06/2024 14:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240628:nRSb4164Ua&default-theme=true

RNS Number : 4164U  Arecor Therapeutics PLC  28 June 2024

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

 

RESULT OF AGM

Change of Name of Nominated Adviser and Joint Broker

 

Cambridge, UK, 28 June 2024: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company advancing today's therapies to enable healthier
lives, announces that at its Annual General Meeting, held today at 12.00 pm,
all resolutions were duly passed.

Change of Name of Nominated Adviser and Broker

The Company also announces that its Nominated Adviser and Joint Broker has
changed its name to Panmure Liberum Limited following completion of its own
corporate merger.

 

 

-ENDS-

 

For more information, please contact:

 Arecor Therapeutics plc                           www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer          Tel: +44 (0) 1223 426060

                                                   Email: info@arecor.com

 Susan Lowther, Chief Financial Officer            Tel: +44 (0) 1223 426060

                                                   Email: info@arecor.com

 Mo Noonan, Communications                         Tel: +44 (0) 7876 444977

                                                   Email: mo.noonan@arecor.com

 Panmure Liberum Limited (NOMAD and Broker)        Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Financial Advisor)               Tel: +44 (0)203 705 9321

 Nigel Barnes, Satheesh Nadarajah

 David Wilson, Claes Spang

 Consilium Strategic Communications                Tel: +44 (0) 20 3709 5700

 Chris Gardner, David Daley, Lindsey Neville       Email: arecor@consilium-comms.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSEDFDAELSEDM